Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $1.2 million.

  • Mereo BioPharma Group's Non-Current Assets fell 40.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 40.93%. This contributed to the annual value of $1.6 million for FY2024, which is 40.60% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Non-Current Assets is $1.2 million, which was down 1.24% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Non-Current Assets peaked at $36.5 million during Q4 2021, and registered a low of $1.2 million during Q3 2025.
  • In the last 3 years, Mereo BioPharma Group's Non-Current Assets had a median value of $1.8 million in 2024 and averaged $1.9 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 93.93% in 2022, then grew by 23.60% in 2023.
  • Mereo BioPharma Group's Non-Current Assets (Quarterly) stood at $36.5 million in 2021, then plummeted by 93.93% to $2.2 million in 2022, then increased by 23.60% to $2.7 million in 2023, then plummeted by 40.60% to $1.6 million in 2024, then plummeted by 40.93% to $1.2 million in 2025.
  • Its Non-Current Assets stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.4 million for Q1 2025.